From: CD38 is methylated in prostate cancer and regulates extracellular NAD+
Characteristic | No recurrence (n = 499) | Recurrence (n = 499) | p value |
---|---|---|---|
Age at surgery | 59.0 (6.0) | 58.8 (6.3) | Matched |
Race | Â | Â | Matched |
 AA | 39 (7.8%) | 47 (9.4%) |  |
 White | 440 (88.2%) | 426 (85.4%) |  |
 Other | 11 (2.2%) | 19 (3.8%) |  |
Gleason sum | Â | Â | Matched |
 5 | 3 (0.6%) | 3 (0.6%) |  |
 6 | 69 (13.8%) | 68 (13.6%) |  |
 7 | 314 (62.9%) | 305 (61.1%) |  |
 8 | 113 (22.6%) | 123 (24.6%) |  |
S stage | Â | Â | Matched |
 1 | 67 (13.4%) | 66 (13.2%) |  |
 2 | 260 (52.1%) | 260 (52.1%) |  |
 3 | 172 (34.5%) | 173 (34.7%) |  |
Pre-op PSA | 11.0 (8.3) | 12.3 (10.2) | 0.026 |
Surgical margins + | 110 (22.0%) | 176 (35.3%) | < 0.001 |